Ukwelashwa kwe-CAR - T Cell, I-CAR T Therapy, ISIMOTO SEMOTO, i-agent ye-chimeric
Ukugxumela Okujulile Ku-CAR T Cell Therapy: Isebenza Kanjani?
Zitholele isayensi ngemuva kokwelashwa kwe-CAR T Cell eNdiya! Hlola ukuthi lokhu kwelashwa okuguquguqukayo kuwaguqula kanjani amaseli akho omzimba abe yizilwi zomdlavuza. Funda ibhulogi yethu manje ukuze ufunde kabanzi mayelana nalokhu kwelashwa okuyisimangaliso nokuthi kanjani ..
Ukwelashwa kwe-CAR - T Cell, ISIMOTO SEMOTO, I-Chimeric Agent Receptor, Korea, Seoul, INingizimu Korea
Izinkampani zaseKorea zithatha igxathu eliseduze ekuthuthukiseni i-CAR T-Cell etshalwe ekhaya
Meyi 2023: I-Chimeric antigen receptor (CAR) I-T-cell therapy intuthuko entsha emkhakheni wokwelashwa komdlavuza ngamunye. Ama-T-cell esiguli ashintshwa ngokofuzo ngesikhathi senqubo yokukhiqiza ukuze aveze a..
biotechnology, Ukwelashwa kwe-CAR - T Cell, ISIMOTO SEMOTO, Ukwelashwa kweCAR, China, ukukhushulwa kwezimali, I-Oricell Therapeutics
I-Oricell inyusa u-$45M USD owengeziwe ukuze inwebise ukwelashwa kwayo kwe-CAR T-Cell iye e-United States
Ngomhla zingama-23 kuNdasa 2023: Izindlela zokwelapha zomdlavuza ezitholakala ngaphambi kwesikhathi kanye nesigaba sokuqala somdlavuza ezithuthukiswa yi-Shanghai biotech Oricell bathole enye imali eyizigidi ezingama- $ 45, kumemezele inkampani ngoLwesibili. Kulandela umbukiso e-AS..
Australia, Ukwelashwa kwe-CAR - T Cell, I-CAR T Therapy, I-Cartherics
I-Peter MacCallum Cancer Centre kanye neCartherics bazosebenzisana ekwelapheni umdlavuza wesibeletho i-CAR-T cell
Mashi 2023: Peter MacCallum Cancer Center (Peter Mac) e-Australia kanye neCartherics Pty Ltd bangene esivumelwaneni sohlelo lokuthuthukisa ngokuhlanganyela (CDPA) sokuthuthukisa i-CTH-002 yokwelapha umdlavuza wesibeletho. I-cli..
Ukwelashwa kwe-CAR - T Cell, ISIMOTO SEMOTO, Emily Littlejohn, I-Immunology, ukuvuselelwa kwe-lupus
Isidakamizwa esisha se-CAR T-Cell ku-lupus renaissance
Feb 2024: Imithi eminingana emisha nemithi ethembisayo, efana ne-chimeric antigen receptor T-cell therapy, ingenise "ukuvuselelwa" kwe-lupus, ngokusho kwesikhulumi ku-symposium Basic and Clinical Immunology for the Busy.
i-anti-BCMA, Ukwelashwa kwe-CAR - T Cell, I-CT103A, FDA, I-IASO Biotherapeutics, I-Innovent Biologics, igama lesidakamizwa sezintandane
I-CT103A, i-CAR T-cell Therapy, iqokwe njengesidakamizwa sezintandane yi-FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
Ukwelashwa kwe-CAR - T Cell, China, I-IASO Biotherapeutics, i-myeloma eminingi
Ukwelashwa kwe-CAR T-cell evela ku-IASO Biotherapeutics kuthola imvume entsha ye-FDA
Feb 2023: I-IASO Biotherapeutics' yocwaningo lwe-CAR T-cell therapy ye-multiple myeloma (RRMM) ebuyele emuva noma ephindwayo, i-CT103A, ithole amagama asheshayo kanye nemithi evuselelayo yokwelapha ethuthukisiwe evela e-US Food and.
Ukwelashwa kwe-CAR - T Cell, Seoul, INingizimu Korea
I-AMC ivula isikhungo se-CAR T-Cell therapy eSeoul
Jan 2023: I-Asan Medical Center (AMC) yavula indawo yokuqala yokwelapha amaseli e-CAR-T ezweni ngemuva kokuthi uhulumeni egunyaze izinzuzo zomshwalense wezempilo we-Kymriah's CAR-T cell therapy.
Ukuhlolwa kwegazi, Ukwelashwa kwe-CAR - T Cell, I-JAMA Oncology, I-neurofilament light chain, Izinkinga ze-Neurotoxic, I-Washington University
Izinkinga zokwelashwa kwe-CAR T-Cell zingabikezelwa ngokuhlolwa kwegazi okulula
Sept 2022: Ukwelashwa kwamathumba ahlukahlukene kuguqulwe i-cell-based immunotherapy, evame ukwaziwa ngokuthi i-CAR-T cell therapy. Ukuze uqondise futhi ulwe nezinhlobo ezithile ze-leukemia ne-lymphoma, ukwelashwa kusebenzisa izakhi zofuzo.
Ukwelashwa kwe-CAR - T Cell, Inkampani CARsgen Therapeutics Co, Inkampani kaDaiichi Sankyo, I-DLBCL, Ucwaningo lwe-Emergen, Limited, I-Novartis AG
Imakethe ye-CAR T-Cell therapy izokhula ngezinga elimangalisayo eminyakeni eyi-8 ezayo
NgoJulayi 2022: Ngokocwaningo lwakamuva olwenziwe yi-Emergen Research, imakethe yomhlaba wonke yokwelashwa ngamaseli e-CAR T ifinyelele kusayizi we-USD 1.29 billion ngo-2021 futhi kulindeleke ukuthi ibhalise i-CAGR yemali engenayo yamaphesenti angama-24.9 ..